Price of Isatuximab-irfc

Isatuximab (Isatuximab-irfc) is a biological agent against leukemia and multiple myeloma (MM), which belongs to the monoclonal antibody class. Its development and launch marks a major advance in the field of oncology treatment, providing an effective treatment option for those suffering from multiple myeloma.

Isatuximab is not yet available in China and cannot be purchased. The price of isatuximab will vary based on a variety of factors, including the patient's country or region, health insurance coverage, treatment plan, dosage and source of purchase. Additionally, the price of a drug may change over time.

The mechanism of isatuximab is mainly by inhibiting the growth and spread of multiple myeloma cells, while prompting the immune system to better attack cancer cells. This drug is an immunomodulator that achieves its therapeutic effects by targeting specific molecular targets. It targets CD38, a protein found on the surface of multiple myeloma cells. By binding to CD38, isatuximab induces apoptosis (cell death) in multiple myeloma cells and inhibits their proliferation. Additionally, the antibody activates immune cells, such as natural killer cells, to attack multiple myeloma cells.

The efficacy of isatuximab has been demonstrated in clinical trials. Multiple clinical studies have shown that isatuximab has clear advantages in prolonging patient survival and improving disease control compared with other treatments. This drug is often combined with other anticancer drugs and immune modulators to enhance the effectiveness of treatment. Patients usually receive regular treatment under the supervision of a doctor to ensure that the disease is under control.

Although isatuximab shows great promise in treating multiple myeloma, it can also cause some side effects. Common side effects include infection, anemia, thrombocytopenia, nausea, vomiting, and fatigue. These side effects are usually monitored and managed during treatment.